ArticleAmerican journal of translational research2026
Improved cardiac function and quality of life with initial macitentan-tadalafil combination therapy compared to tadalafil alone in pulmonary arterial hypertension.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPulmonary arterial hypertension (PAH) is a progressive disease leading to right ventricular failure. The purpose of this study was to evaluate the effects of macitentan combined with tadalafil versus tadalafil monotherapy on cardiac function and quality of life (QOL) in PAH patients.
methodsThis retrospective analysis involved patients identified with PAH who commenced regular therapy between April 2024 and April 2025. Participants were divided into two groups according to their treatment regimen: tadalafil monotherapy (TM) and macitentan combined with tadalafil (MCT). Hemodynamic values, laboratory biomarkers, exercise capacity, and patient-reported outcomes were assessed at baseline and after 6 months of treatment.
resultsIn total, 217 patients were analyzed (TM group: 114; MCT group: 103). After 6 months, the MCT group demonstrated significantly greater improvements in mean pulmonary arterial pressure (38.73 vs. 40.31 mmHg, P=0.029), cardiac index (2.93 vs. 2.61 L/min/m
conclusionsInitial combination therapy with macitentan and tadalafil provides superior hemodynamic, functional, and QOL benefits compared to tadalafil monotherapy in patients with PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.